Have ALLHAT, ANBP2, ASCOT-BPLA, and so forth improved our knowledge about better hypertension care?

Hypertension

Volumn 48, Issue 1, 2006, Pages 1-7

  Sawicki, Peter T ^a   McGauran, Natalie ^a  

^a INSTITUTE FOR QUALITY AND EFFICIENCY IN HEALTH CARE IQWIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORTALIDONE; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; HYDRALAZINE; HYDROCHLOROTHIAZIDE; LISINOPRIL; PERINDOPRIL; RESERPINE; THIAZIDE DIURETIC AGENT; CALCIUM CHANNEL BLOCKING AGENT;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL PROTOCOL; CLINICAL TRIAL; CORONARY RISK; DOSE CALCULATION; DRUG RESEARCH; FOLLOW UP; HEART FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; ISCHEMIC HEART DISEASE; MAXIMUM TOLERATED DOSE; PRIORITY JOURNAL; RENAL PROTECTION; RISK FACTOR; SAMPLE SIZE; SHORT SURVEY; STROKE; SYSTOLIC HYPERTENSION; AGED; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; FEMALE; MALE; MIDDLE AGED; MORTALITY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; SODIUM CHLORIDE SYMPORTER INHIBITORS; TREATMENT OUTCOME;

EID: 33745979161     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000226145.49783.a9     Document Type: Short Survey

References (39)

1. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. I: results in patients with diastolic blood pressure averaging 115 through 129 mm Hg. JAMA. 1967;202:1028-1034.
2. Materson BJ, Cushman WC, Goldstein G, Reda DJ, Freis ED, Ramirez EA, Talmers FN, White TJ, Nunn S, Chapman RH. Treatment of hypertension in the elderly. I. Blood pressure and clinical changes. Results of a Department of Veterans Affairs Cooperative Study. Hypertension. 1990;15:348-360.
3. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304:405-412.
4. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Aldermann MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289:2534-2544.
5. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens. 2003;21:1055-1076.
6. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ, National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
7. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-1053. (Corrections. 2003;21:2203-2204 and 2004;22:435.)
8. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, Thom SM; BHS guidelines working party, for the British Hypertension Society. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ. 2004;328:634-640. (Correction. 2004;328:926.)
9. McInnes GT, Yeo WW, Ramsay LE, Moser M Cardiotoxicity and diuretics: much speculation-little substance. J Hypertens. 1992;10:317-335. (Correction. 1992;10:following H24.)
10. Moser M. Why are physicians not prescribing diuretics more frequently in the management of hypertension? JAMA. 1998;279:1813-1816.
11. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT Jr., Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM, Alderman MH, Ford CE, Oparil S, Francis C, Proschan M, Pressel S, Black HR, Hawkins CM. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens. 1996;9:342-360.
12. The ALLHAT officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997. (Corrections. 2003;289:178 and 2004;291:2196.)
13. The ALLHAT officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to Doxazosin vs. Chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2000;283:1967-1975. (Correction. 2002;288:2976.)
14. Neaton JD, Kuller LH. Diuretics are color blind. JAMA. 2005;293:1663-1666.
15. Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr., Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber M, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T. Renal outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165:936-946.
16. Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber MA, Franklin S, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T; ALLHAT Collaborative Research Group. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med. 2006;144:172-180.
17. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR; SHEP Collaborative Research Group. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005;95:29-35.
18. Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension. 2000;35:1025-1030.
19. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension. 2004;43:4-9.
20. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ; Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583-592.
21. Reid CM, Wing LM, Graham DH. A new paradigm for funding cardiovascular-outcome research in general practice. The second Australian National Blood Pressure Study. ANBP2 Management Committee. Med J Aust. 1998;169:349-350.
22. Reid CM, Ryan P, Nelson M, Beckinsale P, McMurchie M, Gleave D, DeLoozef F, Wing LM; ANBP2 Management Committee. General practitioner participation in the second Australian National Blood Pressure Study (ANBP2). Clin Exp Pharmacol Physiol. 2001;28:663-667.
23. Management Committee on behalf of the High Blood Pressure Research Council of Australia. Australian comparative outcome trial of angiotensin-converting enzyme inhibitor and diuretic-based treatment of hypertension in the elderly (ANBP2): objectives and protocol. Clin Exp Pharmacol Physiol. 1997;24:188-192.
24. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens. 2001;19:1139-1147.
25. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906.
26. Messerli FH, Grossman E, Goldbourt U. Are β-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA. 1998;279:1903-1907.
27. Lindholm LH, Carlberg B, Samuelsson O. Should β-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366:1545-1553.
28. Montori VM, Devereaux PJ, Adhikari NK, Burns KE, Eggert CH, Briel M, Lacchetti C, Leung TW, Darling E, Bryant DM, Bucher HC, Schunemann HJ, Meade MO, Cook DJ, Erwin PJ, Sood A, Sood R, Lo B, Thompson CA, Zhou Q, Mills E, Guyatt GH. Randomized trials stopped early for benefit. A systematic review. JAMA. 2005;294:2203-2209.
29. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, Kastarinen M, Poulter N, Primatesta P, Rodriguez-Artalejo F, Stegmayr B, Thamm M, Tuomilehto J, Vanuzzo D, Vescio F. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA. 2003;289:2363-2369.
30. Psaty BM, Manolio TA, Smith NL, Heckbert SR, Gottdiener JS, Burke GL, Weissfeld J, Enright P, Lumley T, Powe N, Furberg CD; Cardiovascular Health Study. Time trends in high blood pressure control and the use of antihypertensive medications in older adults: the Cardiovascular Health Study. Arch Intern Med. 2002;162:2325-2332.
31. Borzecki AM, Wong AT, Hickey EC, Ash AS, Berlowitz DR. Hypertension control. How well are we doing? Arch Intern Med. 2003;163:2705-2711.
32. Steven ID, Wing L. Control and cardiovascular risk factors of hypertension. An assessment of a sample of patients. Aust Fam Physician. 1999;28:45-48.
33. Weinehall L, Ohgren B, Persson M, Stegmayr B, Boman K, Hallmans G, Lindholm LH. High remaining risk in poorly treated hypertension: the "rule of halves" still exists. J Hypertens. 2002;20:2081-2088.
34. Whelton PK, He J, Muntner P. Prevalence, awareness, treatment and control of hypertension in North America, North Africa and Asia. J Hum Hypertens. 2004;18:545-551.
35. Benson J, Britten N. Patients' decisions about whether or not to take antihypertensive drugs: qualitative study. BMJ. 2002;325:873.
36. Woolf SH, Chan EC, Harris R, Sheridan SL, Braddock CH III, Kaplan RM, Krist A, O'Connor AM, Tunis S. Promoting informed choice: transforming health care to dispense knowledge for decision making. Ann Intern Med. 2005;143:293-300.
37. Trocha AK, Schmidtke C, Didjurgeit U, Muhlhauser I, Bender R, Berger M, Sawicki PT. Effects of intensified antihypertensive treatment in diabetic nephropathy: Mortality and morbidity results of a prospective controlled 10-year study. J Hypertens. 1999;17:1497-1503.
38. Fahey T, Schroeder K, Ebrahim S. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev. 2005;1:CD005182.
39. U.S. Department of Health and Human Services, NIH news, National Institutes of Health. Landmark Hypertension Treatment Study Launches Extensive Physician and Patient Education Program to Improve Public Health. Available at: http://www.nih.gov/news/pr/feb2006/nhlbi-01.htm. Accessed February 1, 2006.